The operating result developed particularly strongly. The result rose by 5.6 per cent to 6.1 billion euros. However, significant currency effects had a negative impact, primarily due to the strong dollar. Nevertheless, the Executive Board and Supervisory Board once again proposed a stable dividend of 2.20 euros per share to shareholders. This development was driven by several strategic business areas. In the Life Science division, solutions for the production of biopharmaceuticals generated strong demand. At the same time, the Group's electronics business benefited from the boom in the semiconductor industry, particularly for materials for modern AI chips. Merck also strengthened its portfolio in the healthcare business. New therapies for rare diseases and established drugs for cardiovascular and metabolic diseases contributed to growth. With the acquisition of the US company SpringWorks, the Group also further expanded its oncology and speciality therapies. Merck expects sales of between EUR 20 and 21.1 billion for 2026. Despite possible currency burdens, the company believes it is well equipped for the next chapter of its growth thanks to its position in biotechnology, semiconductor materials and speciality pharma.
Article from "Merck KGaA" dated 5 March 2026